• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Tyra Biosciences (TYRA) Is Up 12.7% After Wedbush Highlights Pipeline Momentum And Leadership Refresh - What's Changed

    Simply Wall St·12/20/2025 13:15:37
    Listen to the news
    • In December 2025, Wedbush highlighted Tyra Biosciences’ advancing clinical pipeline, pointing to upcoming Phase 2 data in 2026 and a planned Phase 2 trial in upper tract urothelial carcinoma, while the company refreshed its leadership with new chief operating and regulatory officers.
    • The combination of maturing late-stage programs and strengthened executive oversight underscores how Tyra is positioning itself to potentially move targeted therapies to market more efficiently.
    • We’ll now consider how Wedbush’s focus on Tyra’s Phase 2 pipeline momentum and leadership upgrades shapes the company’s broader investment narrative.

    These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

    What Is Tyra Biosciences' Investment Narrative?

    To own Tyra Biosciences, you really have to believe its FGFR3-focused platform can turn multiple Phase 2 shots on goal into eventual commercial products, despite zero revenue and widening losses. The Wedbush call, with a higher price target and “Best Ideas” inclusion, essentially puts a spotlight on 2026 as a make-or-break year, with readouts in intermediate‑risk non‑muscle invasive bladder cancer and achondroplasia plus a planned upper tract urothelial carcinoma trial. That makes clinical data quality, trial execution and regulatory interactions the key short term catalysts. The fresh hires in regulatory and operations look material here, because they directly touch those levers. At the same time, the recent share price surge means any clinical disappointment, delay or safety signal could hit sentiment harder than before.

    However, there is a specific execution risk around those tightly packed 2026 milestones that investors should understand. Our expertly prepared valuation report on Tyra Biosciences implies its share price may be too high.

    Exploring Other Perspectives

    TYRA 1-Year Stock Price Chart
    TYRA 1-Year Stock Price Chart
    With just 1 Tyra fair value estimate from the Simply Wall St Community at US$15, you are seeing a single, more cautious view against the recent optimism around Phase 2 data and leadership upgrades that could reshape expectations.

    Explore another fair value estimate on Tyra Biosciences - why the stock might be worth as much as $15.00!

    Build Your Own Tyra Biosciences Narrative

    Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Want Some Alternatives?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.